Results 131 to 140 of about 53,462 (149)

Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers.

Journal of Clinical Oncology, 2023
116 Background: Although immune checkpoint inhibitors (CPI) are inactive as monotherapy for microsatellite stable (MSS) mCRC, preclinical modeling suggests that addition of other immune-oncology agents can produce antitumor activity.
Danielle M. Pastor, J. Redman, C. Floudas, E. Lamping, D. Francis, L. Cordes, J. Marté, J. Schlom, J. Gulley, J. Strauss   +9 more
semanticscholar   +1 more source

Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers

Journal of Immunology, 2022
Key Points Healthy volunteers were treated with N-803, an IL-15 superagonist. N-803 was safe and had predictable pharmacokinetics. N-803 mediated robust pharmacodynamic effects on CD8+ T cells and NK cells.
M. Rubinstein, Cameron Williams, C. Mart, J. Beall, L. Macpherson, J. Azar, M. Swiderska-syn, P. Manca, B. Gibney, M. Robinson, C. Krieg, Elizabeth G. Hill, S. Taha, A. Rock, John H. Lee, P. Soon-Shiong, J. Wrangle   +16 more
semanticscholar   +1 more source

The wall-associated kinase-like gene RL1 contributes to red leaves in sorghum.

The Plant Journal, 2022
Red leaves are common in trees but rare in cereal crops. Red leaves can be used as raw materials for anthocyanin extraction and may have some adaptive significance for plants.
Ya Lv, Jun Chen, Mengjiao Zhu, Yishan Liu, Xiaoyuan Wu, Xin Xiao, N. Yuyama, Fengxia Liu, Haichun Jing, H. Cai   +9 more
semanticscholar   +1 more source

Positive efficacy and safety phase 3 results in both CIS and papillary cohorts BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) after IL-15RαFc superagonist N-803 (Anktiva) and BCG infusion.

Journal of Clinical Oncology, 2022
431 Background: N-803, a high affinity IL-15 immunostimulatory fusion protein promotes proliferation and activation of natural killer (NK) cells and CD8+ T cells, but not T reg cells.
Sam S. Chang, K. Chamie, M. Gonzalgo, E. Kramolowsky, W. Sexton, S. Reddy, P. Bhar, Megan Huang, P. Soon-Shiong   +8 more
semanticscholar   +1 more source

PLLBA-01 FINAL CLINICAL RESULTS OF PIVOTAL TRIAL OF IL-15RΑFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CIS AND PAPILLARY COHORTS

Journal of Urology, 2022
INTRODUCTION AND OBJECTIVE: Patients with NMIBC CIS unresponsive to BCG have limited treatment options. N-803 (Anktiva) is a mutant IL-15-based immunostimulatory fusion protein complex (IL15RaFc) that promotes proliferation and activation of natural ...
Sam Chang, K. Chamie, M. Hidalgo, E. Kramolowsky, W. Sexton, S. Reddy, P. Soon-Shiong   +6 more
semanticscholar   +1 more source

Promising survival and disease control in third-line or greater metastatic or locally advanced pancreatic cancer patients following chemo-radiation and novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.

Journal of Clinical Oncology, 2022
582 Background: Pancreatic cancer claimed an estimated 47,050 lives in the USA in 2020, with an expected median overall survival (OS) of 3 months in 3rd line. (Manax ASCO GI 2019), with no evidence of disease control in these late stage patients.
T. Seery, C. Nangia, H. McKean, L. Sender, P. Bhar, S. Reddy, P. Soon-Shiong   +6 more
semanticscholar   +1 more source

Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients.

, 2021
510Background: Patients with NMIBC CIS unresponsive to BCG have limited treatment options. N-803 (Anktiva) is a mutant IL-15-based immunostimulatory fusion protein complex (IL-15RαFc) that promotes...
K. Chamie, Sam S. Chang, M. Gonzalgo, E. Kramolowsky, W. Sexton, S. Reddy, Paul Bhar, C. Garner, P. Soon-Shiong   +8 more
semanticscholar   +1 more source